Click here to visit Company website

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. The company is developing NicVAX, a proprietary investigational vaccine under Phase III clinical trial for treatment of nicotine addiction and prevention of smoking relapse.